Clinical Trials Logo

Maternal Opioid Use Disorder clinical trials

View clinical trials related to Maternal Opioid Use Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT03291847 Completed - Clinical trials for Opioid Exposed Infant

Maternal Buprenorphine-naloxone Treatment and the Infant

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this mechanistic study is to evaluate the effects that maternal buprenorphine-naloxone maintenance have on the neurobehavioral development of the fetus and infant. To accomplish this, the investigators will study a sample of 120 opioid dependent pregnant women that will receive buprenorphine-naloxone as part of substance abuse treatment at a comprehensive care treatment facility for pregnant and parenting women with substance use disorders. Fetal neurobehavior and maternal physiology will be assessed, via an established maternal-fetal data acquisition system, at 4 points during gestation: 24, 28, 32 and 36 weeks. Infant birth parameters and Neonatal Abstinence Syndrome (NAS) spectrum display will be evaluated at birth, and infant neurodevelopment will be assessed during the first month of life.